Exelon Patch 15 contains rivastigmine 27mg, a cholinesterase inhibitor used primarily for the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. This transdermal patch delivers a continuous dose of rivastigmine through the skin over 24 hours, providing steady plasma levels and improving cognitive function by enhancing cholinergic neurotransmission in the brain. Rivastigmine works by inhibiting the enzymes acetylcholinesterase and butyrylcholinesterase, which break down acetylcholine, a neurotransmitter important for memory and learning. The Exelon Patch 15 is designed for once-daily application, offering convenience and improved adherence compared to oral formulations. It is typically started at a lower dose and gradually increased to minimize side effects such as nausea, vomiting, and skin irritation at the application site. Patients should apply the patch to clean, dry, and hairless skin on the upper back, chest, or upper arm, rotating the site daily to reduce the risk of skin reactions. Exelon Patch 15 should be used under medical supervision, with regular monitoring to assess therapeutic response and tolerability. It is not a cure but may help slow cognitive decline and improve quality of life in affected individuals.